Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | MCLA-145 |
Indication/Tumor Type | lung cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung cancer | predicted - sensitive | MCLA-145 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MCLA-145 treatment inhibited tumor growth in a cell line xenograft model of CD274 (PD-L1) and NY-ESO-positive lung cancer that had adoptive transfer of human T-cells expressing NY-ESO specific T-cell receptors (Cancer Res 2019;79(13 Suppl):Abstract nr 539). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137 | Full reference... |